Overview
SILEX Systems Ltd (ASX: SLX) is a technology commercialisation company with a high-risk, high-potential profile that reflects its work across laser enrichment, silicon applications and medical isotope development. The shares last traded at A$4.40, down A$0.05 or 1.12%, leaving the company valued at about 1.2B. For investors, the story is less about near-term earnings and more about whether its intellectual property can be converted into durable commercial outcomes.
SILEX Systems operates as a technology commercialisation business rather than a traditional industrial supplier or software platform. Its operations are organised across Silex Systems, Translucent and Silex USA, with a focus on research, development, commercialisation and licensing of the SILEX laser enrichment technology. The company also sells its cREO technology. Its stated applications span uranium enrichment for nuclear power, silicon enrichment for quantum computing and medical isotope enrichment for cancer therapies, which gives the business exposure to several advanced-technology and specialist end-markets. That breadth is strategically interesting, but it also means value creation depends on execution across multiple long-duration development paths.
Key facts
- Ticker
- SLX
- Exchange
- AU
- ISIN
- AU000000SLX4
- Sector
- Technology
- Industry
- Semiconductors
- Country
- Australia
- Currency
- AUD
- Price
- A$4.19
- Previous close
- A$4.19
- Day change
- A$0.00 (0.00%)
- Market cap
- 1.2B
- 52W low
- A$4.07
- 52W high
- A$10.85
Price and trend
Last price: A$4.19
- Price
- A$4.19
- 52W range
- A$4.07 – A$10.85
- 50-day SMA
- A$4.89
- 200-day SMA
- A$5.85
- Price vs 50D SMA
- -14.30%
- Price vs 200D SMA
- -28.39%
Valuation
- P/E
- 0.00
- PEG
- 3.88
- EPS
- -0.14
- Beta
- 0.48
Valuation remains difficult to anchor to conventional earnings metrics because the company is still loss-making, with earnings per share of -A$0.14 and a negative profit margin of -2.05%. Revenue over the trailing 12 months is A$18.9M, while revenue growth is shown as 0.00%, underscoring that the near-term financial profile is modest relative to the company’s A$1.2B market capitalisation. The PE ratio is not meaningful at 0, and the PEG ratio of 3.88 offers only a limited guide in a business where commercial milestones matter more than current profits. Against that backdrop, the A$10.36 target price implies a 135.45% difference from the last price, but that should be read as secondary context rather than a forecasting anchor given the uncertainty typical of technology commercialisation businesses.
Profitability and growth
- Revenue growth
- 0.00%
- Revenue TTM
- 18.9M
- Profit margin
- -2.05%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
- Price
- A$4.19
- Target price
- A$10.36
- Target vs last price
- 147.26% from last price
The broader market appears to be pricing SLX as a story stock with optionality rather than a steady cash-generating compounder. The share price of A$4.40 sits below the 50-day moving average of A$4.91 and the 200-day moving average of A$5.92, which suggests the medium-term trend has been softer than the longer-run average. It is also trading near the lower end of its 52-week range, with the year’s low at A$4.07 and high at A$10.85. Beta of 0.484 points to lower headline volatility than the market overall, but that does not remove the business risk attached to commercialisation, regulatory pathways and the timing of potential licensing or deployment outcomes. The absence of a dividend yield also means investors are relying entirely on future capital appreciation rather than income while the business scales.
Risks
The main risk is that SLX’s valuation depends on technologies that may take time to commercialise, with no guarantee that development effort converts into meaningful revenue or profits. The company’s negative EPS and profit margin show that it is still investing ahead of earnings, and the current revenue base remains relatively small. Share price performance also reflects this uncertainty, with the stock trading below both the 50-day and 200-day averages. Even though beta is low, the underlying investment case can still be sensitive to project milestones, partner interest, funding needs and sentiment around advanced technology themes such as nuclear fuel services, quantum computing and medical isotopes. Investors also need to consider that a wide gap between the current share price and the target price does not remove execution risk.
FAQ
What does SILEX Systems do?
SILEX Systems is a technology commercialisation company focused on research, development, commercialisation and licensing of laser enrichment technology. It also has exposure to silicon enrichment for quantum computing and medical isotope enrichment for cancer therapies.
Is SILEX Systems profitable?
Based on the supplied figures, no. The company has earnings per share of -A$0.14 and a profit margin of -2.05%.
Does SILEX Systems pay a dividend?
No dividend yield is shown in the supplied data, so the company is not currently presenting as an income stock.
How has the share price been trading relative to its recent averages?
The last price of A$4.40 is below both the 50-day moving average of A$4.91 and the 200-day moving average of A$5.92, which points to weaker recent momentum.
What is the 52-week trading range for SLX?
The shares have traded between A$4.07 and A$10.85 over the past 52 weeks.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
Silex Systems Limited (ASX: SLX) Fundamentals
